|1.||Watanabe, Kunihiro: 1 article (01/2003)|
|2.||Yoshida, Daizo: 1 article (01/2003)|
|3.||Sugisaki, Yuichi: 1 article (01/2003)|
|4.||Teramoto, Akira: 1 article (01/2003)|
|5.||Takahashi, Hiroshi: 1 article (01/2003)|
|6.||Maeda, H: 1 article (04/2001)|
|7.||Okuyama, A: 1 article (04/2001)|
|8.||Hayashida, K: 1 article (04/2001)|
|9.||Okamoto, T: 1 article (04/2001)|
|10.||Wu, J: 1 article (04/2001)|
01/01/2003 - "The aim of the study was to investigate whether the cytotoxicity of BE16627B, an anti-MMP agent, is related to apoptosis in the human malignant glioma cell lines U87MG, U251MG, and U373MG. "
03/01/2001 - "The aim of this study was to investigate whether inhibition of MMP activity in malignant glioma cells could be achieved by a novel agent, BE16627B (BE). "
01/01/2003 - "These results indicated that cytotoxic concentrations of BE16627B induced apoptosis in human malignant glioma cell lines. "
01/01/2003 - "We have elucidated the pharmacological action of the anti-matrix metalloproteinase inhibitor BE16627B on glioma cells. "
01/01/2003 - "Apoptotic induction by BE16627B on human malignant glioma cell lines by an anti-matrix metalloproteinase agent."
09/01/1994 - "Thus, BE16627B inhibited metalloproteinase-dependent human tumor-cell growth as well as lung colonization without showing cytotoxicity in nude mice."
09/01/1994 - "BE16627B at 100 micrograms/ml showed no apparent cytotoxicity to human tumor cells in culture and its LD50 in mice was more than 1,000 mg/kg (i.p.). "
04/01/2001 - "MMP inhibitor BE16627B (66.6 mg / kg i.v., given 2 times) or SI-27 (10 mg / kg i.p., given 2 times) significantly suppressed the ONOO(-)-induced EPR effect in S-180 tumors and in normal skin. "
09/01/1994 - "The effects of a new metalloproteinase inhibitor, BE16627B [L-N-(N-hydroxy-2-isobutylsuccinynamoyl)-seryl-L-valine, MW: 375.2] isolated from microbial cultures, on human tumor cell growth in nude mice were investigated. "
07/01/1993 - "The effect of a new metalloproteinase (MP) inhibitor [BE16627B; L-N-(N-hydroxy-2-isobutylsuccinamoyl)-seryl-L-valine, MW: 375.2] isolated from Streptomyces sp. was evaluated by using primary cultures of synovial cells from rheumatoid arthritis patients. "
07/01/1993 - "Inhibition of metalloproteinase activity of rheumatoid arthritis synovial cells by a new inhibitor [BE16627B; L-N-(N-hydroxy-2-isobutylsuccinamoyl)-seryl-L-valine]."